Multiple Myeloma Clinical Trials

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Anniston : Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Birmingham : University of Alabama at Birmingham

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Birmingham : Birmingham Hematology & Oncology Associates Llc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Birmingham : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Huntsville : Clearview Cancer Institute

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Huntsville : Clearview Cancer Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Huntsville : The Cancer Center of Huntsville

Connect® MM- The Multiple Myeloma Disease Registry

Mobile : Providence Cancer Center at Providence Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muscle Shoals : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Tuscaloosa : DCH Health System

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Anchorage : Providence Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Phoenix : Arizona Oncology Associates

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Scottsdale :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Scottsdale : Mayo Clinic Arizona

Dose-escalation Study of Oral CX-4945

Scottsdale : Mayo Clinic in Arizona Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Scottsdale : Oncology Research Associates

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Scottsdale : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Sedona :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Tucson :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Tucson :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Tucson : US Oncology - Arizona Oncology Associates - Rudasill

Connect® MM- The Multiple Myeloma Disease Registry

Tucson : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Tucson : Acrc/Arizona Clinical Research Center, Inc.

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Fort Smith : St. Edward Mercy Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Hot Springs : Genesis Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Jonesboro : Clopton Clinic Hematology/Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Jonesboro : NEA Medical Clinic - East Matthews

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Little Rock : University of Arkansas Medical Sciences

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Little Rock : University of Arkansas for Medical Sciences

Compassionate Use Study of Carfilzomib

Little Rock : Little Rock Hematology Oncology Associates, PA

Connect® MM- The Multiple Myeloma Disease Registry

Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Little Rock : The University of Arkansas for Medical Sciences

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Little Rock : University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy

UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

Rogers : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

Duarte : City of Hope Updated

A Phase I Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (Protocol ARRAY-520-111)

Duarte : City of Hope Updated

A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma

Duarte : City of Hope Updated

A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma

Duarte : City of Hope Updated

An Open Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF-4539A in Patients with Relapsed or Refractory Multiple Myeloma

Duarte : City of Hope Updated

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Duarte : City of Hope Updated

BMT CTN 0702: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

Duarte : City of Hope Updated

Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients Undergoing Hematopoetic Cell Transplantation (HCT)

Duarte : City of Hope Updated

Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with High Risk Multiple Myeloma

Duarte : City of Hope Updated

SWOG S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment

View More »

Anaheim : Pacific Cancer Medical Center Incorporated

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Anaheim : Pacific Cancer Medical Center, Inc

Connect® MM- The Multiple Myeloma Disease Registry

Anaheim : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Anaheim : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Bakersfield : Comprehensive Blood and Cancer Center (CCBC)

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Bakersfield : Comprehensive Blood and Cancer Center

Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma

Berkeley : Alta Bates Summit Comprehensive Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Berkeley : Alta Bates Summit Comprehensive Cancer Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Burbank :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Burbank : Providence Saint Joseph Medical Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Campbell : Southbay Oncology Hematology Partners

Connect® MM- The Multiple Myeloma Disease Registry

Campbell : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Castro Valley : East Bay Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Castro Valley : Valley Medical Oncology Consultants - Castro Valley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord : Cancer Care Center at John Muir Health - Concord Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Corona : Compassionate Cancer Care Medical Group (Corona)

Connect® MM- The Multiple Myeloma Disease Registry

Corona : Compassionate Cancer Care Medical Group Inc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Corona : Compassionate Cancer Care Medical Group, Inc

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Duarte : City of Hope

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Duarte :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Duarte : City of Hope

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Duarte : City of Hope

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Duarte : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Duarte : City of Hope Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Encinitas : Pacific Oncology and Hematology

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Escondido : Southwest Cancer Care

Connect® MM- The Multiple Myeloma Disease Registry

Fairfield : North Bay Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fountain Valley : Compassionate Cancer Care Medical Group (Fountain Valley)

Connect® MM- The Multiple Myeloma Disease Registry

Fremont : Valley Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fresno : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Fresno : California Cancer Associates For Research and Excellence, cCARE Updated

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Fullerton : Virginia K. Crosson Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenbrae : Marin Cancer Care, Inc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

La Jolla : Moores UCSD Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

La Jolla : UC San Diego Moores Cancer Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

La Jolla : University of California, San Diego

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Lancaster : TORI - Antelope Valley Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Los Angeles : UCLA

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Los Angeles : UCLA Medical School

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Los Angeles : USC/Norris Comprehensive Cancer Center

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles : Ucla Medical Center

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Los Angeles : Ucla Department Of Medicine

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Los Angeles : UCLA Neuro-Oncology Program

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Los Angeles : West Los Angeles VA Medical Center

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Martinez : Contra Costa Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Merced : Mercy Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monterey : Monterey Bay Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Mountain View : El Camino Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Northridge : TORI - North Valley Hematology/Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Oakland : Hematology Oncology Associates

Connect® MM- The Multiple Myeloma Disease Registry

Oakland : Larry G Strieff MD Medical Corporation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Bay Area Breast Surgeons, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Tom K Lee, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Alta Bates Summit Medical Center - Summit Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Highland General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Epic Care - Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : CCOP - Bay Area Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Orange : Medical Oncology Care Associates

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Orange : St. Joseph Hospital Regional Cancer Center - Orange

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Orange : Children's Hospital of Orange County

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Orange : Medical Oncology Care Associates

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Palm Springs : Comprehensive Cancer Center at Desert Regional Medical Center

A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma

Palm Springs : Comprehensive Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Palo Alto : Stanford Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Palo Alto :

Study of KB004 in Subjects With Hematologic Malignancies

Pleasant Hill : Bay Area Cancer Research Group, LLC

Connect® MM- The Multiple Myeloma Disease Registry

Pleasant Hill : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Pleasanton : Valley Medical Oncology Consultants - Pleasanton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pomona : New Hope Cancer & Research Institute

Connect® MM- The Multiple Myeloma Disease Registry

Rancho Cucamonga :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Riverside : Campassionate Cancer Care Medical Group (Riverside)

Connect® MM- The Multiple Myeloma Disease Registry

Roseville : Capitol Hematology Oncology Medical Group - Sutter Roseville

Connect® MM- The Multiple Myeloma Disease Registry

Sacramento : University of California Davis Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salinas : Pacific Cancer Care

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

San Diego : Sharp Clinical Oncology Research

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

San Diego : Sharp Clinical Oncology Research

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

San Francisco : Investigational Site Number 840004

Phase 1 SAR650984 Combination With Lenalidomide

San Francisco : University of California at San Francisco

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

San Francisco : University of California at San Francisco

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

San Pablo : Alta Bates Comprehensive Cancer Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

San Pablo : Doctors Medical Center - San Pablo Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Santa Barbara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Santa Barbara : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Santa Maria : TORI - Central Coast Medical Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Santa Maria : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Santa Maria : Central Coast Medical Oncology

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Santa Maria : Central Coast Medical Oncology

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Santa Rosa : Redwood Regional Medical Group, Inc.

Connect® MM- The Multiple Myeloma Disease Registry

Stanford : Stanford University School of Medicine

Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Stockton : Stockton Hematology Oncology Medical Group, Inc.

Connect® MM- The Multiple Myeloma Disease Registry

Truckee : Tahoe Forest Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

West Hollywood : James R Berenson, MD, Inc.

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

West Hollywood : Berenson Oncology

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

West Hollywood : Institute for Myeloma and Bone Cancer Research

Connect® MM- The Multiple Myeloma Disease Registry

West Hollywood : James R. Berenson MD, Incorporated

Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma

West Hollywood : James R. Berenson M.D., Inc.

Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients

West Hollywood : James R. Berenson, MD, Inc.

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

West Hollywood : James R. berenson, M.D., Inc.

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Aurora : US Oncology- Rocky Mountain Cancer Center-Aurora

Connect® MM- The Multiple Myeloma Disease Registry

Aurora : Aurora Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boulder : US Oncology - Rocky Mountain Cancer Center-Boulder

Connect® MM- The Multiple Myeloma Disease Registry

Boulder : Boulder Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : US Oncology - Rocky Mountain Cancer Center-Colorado Springs

Connect® MM- The Multiple Myeloma Disease Registry

Colorado Springs : US Oncology- Rocky Mountain Cancer Center at the Pavillion

Connect® MM- The Multiple Myeloma Disease Registry

Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Penrose Cancer Center at Penrose Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : RMCC

A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Denver :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Denver :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Denver : Rocky Mountain Cancer Centers

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Denver : Rocky Mountain Cancer Centers - Aurora

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Denver : US Oncology - Rocky Mountain Cancer Center-Rose

Connect® MM- The Multiple Myeloma Disease Registry

Denver : US Oncology - Rocky Mountain Cancer Center-Midtown

Connect® MM- The Multiple Myeloma Disease Registry

Denver : Rocky Mountain Cancer Centers - Denver Midtown

Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma

Denver : Colorado Blood Cancer Institute

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Denver : Colorado Blood Cancer Institute

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Denver : St. Joseph Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Porter Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Rose Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Presbyterian - St. Luke's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : CCOP - Colorado Cancer Research Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Anthony Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Colorado Blood Cancer Institute

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function

Englewood : Swedish Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Front Range Cancer Specialists

Dose-escalation Study of Oral CX-4945

Fort Collins : Front Range Cancer Specialists

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Poudre Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Grand Junction : TORI - St. Mary's Advanced Medical Pavilion

Connect® MM- The Multiple Myeloma Disease Registry

Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greeley : North Colorado Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lakewood : US Oncology - Rocky Mountain Cancer Center-Lakewood

Connect® MM- The Multiple Myeloma Disease Registry

Littleton : US Oncology - Rocky Mountain Cancer Center-Littleton

Connect® MM- The Multiple Myeloma Disease Registry

Littleton : Littleton Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lone Tree : US Oncology - Rocky Mountain Cancer Center-Sky Ridge

Connect® MM- The Multiple Myeloma Disease Registry

Lone Tree : Sky Ridge Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Longmont : US Oncology - Rocky Mountain Cancer Center-Longmont

Connect® MM- The Multiple Myeloma Disease Registry

Longmont : Hope Cancer Care Center at Longmont United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Loveland : Front Range Cancer Specialists

Dose-escalation Study of Oral CX-4945

Loveland : McKee Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parker : US Oncology - Rocky Mountain Cancer Center-Parker

Connect® MM- The Multiple Myeloma Disease Registry

Parker : Parker Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pueblo : St. Mary - Corwin Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Thornton : US Oncology - Rocky Mountain Cancer Center-Thornton

Connect® MM- The Multiple Myeloma Disease Registry

Thornton : North Suburban Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : Exempla Lutheran Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Fairfield : Medical Specialists of Fairfield

Connect® MM- The Multiple Myeloma Disease Registry

Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Manchester : Medical Oncology and Blood Disorders, LLP

Connect® MM- The Multiple Myeloma Disease Registry

New Britain : Hospital of Central Connecticut

Connect® MM- The Multiple Myeloma Disease Registry

New Haven : Yale University School Of Medicine

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

New Haven : Yale University School of Medicine

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

New Haven : Yale University

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

New Haven : Yale University School Of Medicine

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

New Haven : Yale University School Of Medicine

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Stamford : Hematology Oncology, PC

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Lewes : Tunnell Cancer Center at Beebe Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Delaware Clinical & Laboratory Physicians, PA

Connect® MM- The Multiple Myeloma Disease Registry

Newark : CCOP - Christiana Care Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wilmington : Alfred I. duPont Hospital for Children

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Washington : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Washington : Georgetown Lombardi Comprehensive Cancer Center

Phase I Study of CS-7017 and Bexarotene

Washington : Washington Cancer Institute At Washington Hospital Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Washington : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Boynton Beach : University Cancer Institute

Connect® MM- The Multiple Myeloma Disease Registry

Boynton Beach : Hematology Oncology Associates

Connect® MM- The Multiple Myeloma Disease Registry

Boynton Beach : Collaborative Research Group

Connect® MM- The Multiple Myeloma Disease Registry

Boynton Beach : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Boynton Beach : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Brooksville : Cancer Care Centers Of Florida

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Brooksville : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Coral Springs : Flora Research Associates

Connect® MM- The Multiple Myeloma Disease Registry

Deerfield Beach : Flora Research Associates

Connect® MM- The Multiple Myeloma Disease Registry

Deerfield Beach : Archbold Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Fort Lauderdale : Broward Oncology Associates, PA

Connect® MM- The Multiple Myeloma Disease Registry

Fort Lauderdale : Broward General Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Lauderdale : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Fort Lauderdale : Holy Cross Hospital-Bienes Cancer Center

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Fort Myers : Florida Cancer Specialists

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Gainesville : Shands Hospital at University of Florida

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Gainesville : Florida Cancer Specialists & Research Institute

Connect® MM- The Multiple Myeloma Disease Registry

Hollywood : Memorial Cancer Institute

Connect® MM- The Multiple Myeloma Disease Registry

Hudson : US Oncology - Florida Cancer Institute - New Hope-Hudson

Connect® MM- The Multiple Myeloma Disease Registry

Jacksonville :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Jacksonville : Mayo Clinic

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Jacksonville : Integrated Community Oncology Network, LLC

Connect® MM- The Multiple Myeloma Disease Registry

Jacksonville : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Jacksonville : Integrated Community Oncology Network

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Jacksonville : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Jacksonville : Integrated Community Oncology Network

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Lake City : Cancer Care of North Florida

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Lakeland : Watson Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Lecanto : Cancer and Blood Disease Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Lecanto : Cancer & Blood Disease Center

Connect® MM- The Multiple Myeloma Disease Registry

Melbourne : Medical Associate of Brevard (MAB) Oncology/Hematology

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

New Port Richey : US Oncology - Florida Cancer Institute - New Hope-New Port Richey

Connect® MM- The Multiple Myeloma Disease Registry

New Port Richey : Pasco Hernando Oncology Associates (Kumar)

Connect® MM- The Multiple Myeloma Disease Registry

New Port Richey : Cancer Care Centers Of Florida

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ocala :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Ocala : Ocala Oncology Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Orlando : MD Anderson Orlando

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Pensacola : Sacred Heart Medical Oncology Group

Connect® MM- The Multiple Myeloma Disease Registry

Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pensacola : Sacred Heart Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rockledge : Cancer Care Centers of Brevard

Connect® MM- The Multiple Myeloma Disease Registry

St. Petersburg : Florida Cancer Specialists

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Tampa : H. Lee Moffitt Cancer Center & Research Institute

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Tampa : H. Lee Moffitt Cancer Center

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Tampa : Investigational Site Number 840001

Phase 1 SAR650984 Combination With Lenalidomide

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tampa :

Study of KB004 in Subjects With Hematologic Malignancies

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Tampa : Moffitt Cancer Center & Research Institute

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

The Villages : Florida Hospital Waterman-Lake County Oncology & Hematology

Connect® MM- The Multiple Myeloma Disease Registry

Titusville : Space Coast Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

West Palm Beach : Palm Beach Cancer Institute

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

West Palm Beach : Palm Beach Cancer Institute

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

West Palm Beach : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

West Palm Beach : Palm Beach Cancer Institute

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Weston : Cleveland Clinic Florida

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Albany : Phoebe Putney Memorial Hospital

Connect® MM- The Multiple Myeloma Disease Registry

Atlanta : Emory University Winship Cancer Institute

A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Atlanta : Winship Cancer Institute of Emory University

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Atlanta : Emory University, Winship Cancer Institute

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Atlanta : Emory University, Winship Cancer Institute

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Atlanta : Peachtree Hematology-Oncology Consultants

Connect® MM- The Multiple Myeloma Disease Registry

Atlanta : Georgia Cancer Specialists

Connect® MM- The Multiple Myeloma Disease Registry

Atlanta : Emory University Winship Cancer Institute

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Atlanta : Emory University Winship Cancer Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Atlanta : Winship Cancer Institute, Emory University

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Atlanta : Emory University Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Atlanta : Northside Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : CCOP - Atlanta Regional

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Saint Joseph's Hospital of Atlanta

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Piedmont Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Emory University Winship Cancer Institute

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Atlanta : Winship Cancer Institute, Emory University

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Atlanta : Winship Cancer Institute

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Atlanta : Emory University

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Atlanta : Emory University

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Austell : WellStar Cobb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : John B. Amos Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Gwinnett Hospital System Inc-d/b/a The Center for Cancer Care Updated

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Fayetteville : Piedmont Fayette Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gainesville : Northeast Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrenceville : Gwinnett Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Northwest Georgia Oncology Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Riverdale : Southern Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rome : Harbin Clinic Cancer Center - Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Savannah : Summit Cancer Care

Connect® MM- The Multiple Myeloma Disease Registry

Savannah : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Aiea : Kapiolani Medical Center at Pali Momi

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Straub Clinic and Hospital

Connect® MM- The Multiple Myeloma Disease Registry

Honolulu : Tripler Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Kuakini

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Queen's Cancer Institute at Queen's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Hawaii Medical Center - East

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Kapiolani Medical Center for Women and Children

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Cancer Research Center of Hawaii

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Lusitana

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Straub Clinic and Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lihue : Kauai Medical Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Pacific Cancer Institute - Maui

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Maui Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lewiston : St. Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Meridian : Mountain States Tumor Institute - Meridian

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Nampa : Saint Luke's Mountain States Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Twin Falls : Mountain States Tumor Institute at St. Luke's

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland, PC

Connect® MM- The Multiple Myeloma Disease Registry

Aurora : Rush-Copley Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Carbondale : Memorial Hospital of Carbondale

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : John H. Stroger Jr. Hospital of Cook County

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Chicago : University of Chicago

A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Chicago :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Chicago :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Chicago : University Of Chicago Medical Center

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Chicago : University Of Chicago Medical Center

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Chicago : Univeristy of Chicago Medical Center, Section of Hematology/Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Chicago : John H. Stroger, Jr. Hospital of Cook County

Connect® MM- The Multiple Myeloma Disease Registry

Chicago : Rush University Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Chicago : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Chicago : University of IL at Chicago Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Chicago : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Chicago : University of Chicago, School of Medicine

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Chicago : The University Of Chicago

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Chicago : Louis A. Weiss Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : John H. Stroger, Jr. Hospital of Cook County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : The University of Chicago

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Chicago : University Of Chicago Medical Center

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Chicago : University of Chicago Medical Center

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Decatur : Decatur Memorial Hospital Cancer Care Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Decatur : Cancer Care Specialists Of Central Illinois

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Elgin : Sherman Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elmhurst : Elmhurst Memorial Hospital

Connect® MM- The Multiple Myeloma Disease Registry

Evanston : Northshore University Health System

Connect® MM- The Multiple Myeloma Disease Registry

Evanston : Evanston Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Galesburg : Medical and Surgical Specialists

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Geneva : Delnor Hospital - Geneva

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Harvey : Ingalls Cancer Research Center

Connect® MM- The Multiple Myeloma Disease Registry

Hines : Veterans Affairs Medical Center - Hines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hines : Edward Hines Jr VA Hospital

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Joliet : Joliet Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Joliet : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Maywood : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Moline : Medical Arts Associates, Ltd

Connect® MM- The Multiple Myeloma Disease Registry

Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Moline :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Good Samaritan Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Niles : Illinois Cancer Specialists

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Niles : Oncology Specialists, S.C.

Connect® MM- The Multiple Myeloma Disease Registry

Niles : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Park Ridge : Oncology Specialists, S.C.

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Peoria : Illinois Cancer Care

Connect® MM- The Multiple Myeloma Disease Registry

River Forest : West Suburban Center for Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Skokie : Orchard Research

Connect® MM- The Multiple Myeloma Disease Registry

Skokie : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Springfield : Regional Cancer Center at Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Urbana : Carle Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Urbana : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Urbana : CCOP - Carle Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Urbana : Carle Cancer Center

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Warrenville : Central Dupage Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zion : Cancer Centers of America

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Anderson : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Beech Grove : Indiana Blood and Marrow Transplant, LLC

Connect® MM- The Multiple Myeloma Disease Registry

Beech Grove : St. Francis Cancer Research

Connect® MM- The Multiple Myeloma Disease Registry

Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Michiana Hematology-Oncology, PC - Elkhart

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart Clinic, LLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Wayne : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Goshen : IU Health Goshen Hospital Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Goshen : Center for Cancer Care @ Goshen Health Systems

Connect® MM- The Multiple Myeloma Disease Registry

Indianapolis : Indiana University Simon Cancer Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Indianapolis : IU Health Central Indiana Cancer Centers Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Indianapolis : Community Regional Cancer Center Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Indianapolis : Investigative Clinical Research Of Indiana, Llc

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Indianapolis : Indiana University Simon Cancer Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Indianapolis : Indiana University Cancer Center Clinical Research Office

Connect® MM- The Multiple Myeloma Disease Registry

Indianapolis : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Indianapolis : IU Simon Cancer Center

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

Indianapolis : Hematology-Oncology of Indiana, PC

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Indianapolis : Investigative Clinical Research Of Indiana, Llc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Indianapolis : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Indianapolis : Investigative Clinical Research Of Indiana, Llc

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Indianapolis : Franciscan St. Francis Health

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Kokomo : Howard Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lafayette : IU Health Arnett Cancer Center Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Michigan City : Saint Anthony Memorial Health Centers

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Michiana Hematology Oncology, P.C.

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Mishawaka : Saint Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Michiana Hematology-Oncology, PC - South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Munster : Cancer Research-Munster

Connect® MM- The Multiple Myeloma Disease Registry

New Albany : Cancer Care Center Inc.

Connect® MM- The Multiple Myeloma Disease Registry

Newburgh : Oncology Hematology Associates of SW IN

Connect® MM- The Multiple Myeloma Disease Registry

Plymouth : Michiana Hematology Oncology PC - Plymouth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Richmond : Reid Hospital & Health Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : Northern Indiana Cancer Research Consortium

Connect® MM- The Multiple Myeloma Disease Registry

South Bend : Memorial Hospital of South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : CCOP - Northern Indiana CR Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westville : Michiana Hematology Oncology PC - La Porte

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Ames : McFarland Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Ames : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ames : McFarland Clinic Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Ames : McFarland Clinic, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bettendorf : Hematology Oncology Associates of the Quad Cities

Connect® MM- The Multiple Myeloma Disease Registry

Bettendorf :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Cedar Rapids : Iowa Blood and Cancer Care of PCI

Connect® MM- The Multiple Myeloma Disease Registry

Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Cedar Rapids Oncology Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Clive : Medical Oncology and Hematology Associates - West Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Davenport : Genesis Regional Cancer Center at Genesis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : CCOP - Iowa Oncology Research Association

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iowa City : University of Iowa Hospitals

A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Iowa City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Iowa City : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Iowa City : University Of Iowa Hospitals And Clinics

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Siouxland Hematology-Oncology Associates, LLP

Connect® MM- The Multiple Myeloma Disease Registry

Sioux City : Siouxland Hematology Oncology Associates Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Sioux City : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Sioux City : St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Siouxland Hematology-Oncology Associates, LLP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Mercy Medical Center - Sioux City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waterloo : Covenant Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Waterloo : Cedar Valley Medical Specialists

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Chanute : Cancer Center of Kansas, PA - Chanute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dodge City : Cancer Center of Kansas, PA - Dodge City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

El Dorado : Cancer Center of Kansas, PA - El Dorado

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fairway : University of Kansas Medical Center

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Fort Scott : Cancer Center of Kansas - Fort Scott

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Independence : Cancer Center of Kansas-Independence

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kingman : Cancer Center of Kansas, PA - Kingman

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrence : Lawrence Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberal : Cancer Center of Kansas, PA - Liberal

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

McPherson : Cancer Center of Kansas, PA - McPherson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newton : Cancer Center of Kansas, PA - Newton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Saint Luke's Hospital - South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Menorah Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parsons : Cancer Center of Kansas, PA - Parsons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Prairie Village : CCOP - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Prairie Village : Kansas City CCOP

S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Pratt : Cancer Center of Kansas, PA - Pratt

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Tammy Walker Cancer Center at Salina Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Cancer Center of Kansas, PA - Salina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Topeka : Cotton-O'Neil Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wellington : Cancer Center of Kansas, PA - Wellington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Wichita : Cancer Center of Kansas, PA

Connect® MM- The Multiple Myeloma Disease Registry

Wichita : Associates in Womens Health, PA - North Review

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Cancer Center of Kansas, PA - Medical Arts Tower

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Cancer Center of Kansas, PA - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : CCOP - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Winfield : Cancer Center of Kansas, PA - Winfield

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Ashland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Hazard : Kentucky Cancer Clinic

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Hazard : Kentucky Cancer Clinic

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Louisville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Louisville : Baptist Hospital East

Connect® MM- The Multiple Myeloma Disease Registry

Paducah : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Baton Rouge : Mary Bird Perkins Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Baton Rouge : Ochsner Health Center - Bluebonnet

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Covington : Ochsner Health Center - Covington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lafayette : Cancer Center Of Acadiana At Lafayette General

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Lafayette : Cancer Center Of Acadiana

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Monroe : Louisiana State University Health Sciences Center - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : CCOP - Ochsner

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Shreveport : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Shreveport : Highland Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Brewer : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Scarborough : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Updated

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Baltimore : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Baltimore : University of Maryland Medical Center - M & S Greenebaum Cancer Center

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Baltimore : Sidney Kimmel Cancer Center Johns Hopkins Hospital

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Baltimore : University of Maryland, Greenebaum Cancer Center

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Baltimore : Harry & Jeanette Weinberg Cancer Institute

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Baltimore : Greater Baltimore Medical Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Baltimore : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Baltimore : The Sidney Kimmel Comprehensive Cancer Center

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Baltimore : Greater Baltimore Medical Center

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Baltimore : Johns Hopkins University

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Bethesda :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Bethesda : Center for Cancer & Blood Disorders, PC

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Bethesda : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

Lenalidomide Maintenance Therapy for Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Bethesda : Center for Cancer and Blood Disorders

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Bethesda : National Capital Clinical Research Consortium

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Bethesda : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Bethesda : Center for Cancer and Blood Disorders

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Elkton : Union Hospital of Cecil County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rockville :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Rockville :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Rockville : Associates in Oncology/Hematology, P.C.

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Westminster : Alliance Hematology Oncology, PA

Connect® MM- The Multiple Myeloma Disease Registry

Westminster : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Boston : Beth Israel Deaconess Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Boston : Dana Farber Cancer Institute

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Boston : Massachusetts General Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Boston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Boston :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Boston : Dana-Farber Cancer Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Boston : Dana Farber Cancer Institute

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Boston : Dana-Farber Cancer Institute

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Boston : Dana-Farber Cancer Institute

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Boston : Dana-Farber Cancer Institute

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Boston : Dana Farber Cancer Institute

Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma

Boston : Massachusetts General Hospital

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Boston : Dana-Farber Cancer Institute

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Boston : Dana Farber Cancer Institute

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Boston : Dana Farber Cancer Institute

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Boston : Dana-Farber Cancer Institute

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Boston : Dana-Farber Cancer Institute

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Boston : Massachusetts General Hospital

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Boston : Beth Israel Deaconess Medical Center

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Boston : Beth Israel Deaconess Medical Center

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Boston : Massachusetts General Hospital

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Boston : Dana-Farber Cancer Institute

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Boston : Dana-Farber Cancer Institute

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Boston : Tufts Medical Center

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Boston : Dana Farber Cancer Institute

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Boston : Massachusetts General Hospital

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Boston : Massachusetts General Hospital

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Boston : Dana Farber Cancer Institute

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Boston : Beth Israel Deaconess Medical Center

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Boston : Massachusetts General Hospital

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Boston : Dana Farber Cancer Institute

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Hyannis : Capecod Hospital/Davenport Mugar Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Jamaica Plain : VA Boston Healthcare System

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Methuen : Caritas Holy Family Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Worcester : Fallon Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Worcester : University of Massachusetts

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Worcester : Reliant Medical Group, Inc

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Adrian : Hickman Cancer Center at Bixby Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Comprehensive Cancer Center Main Office

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Ann Arbor : Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Ann Arbor : University of Michigan

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Ann Arbor : University Of Michigan

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ann Arbor : Saint Joseph Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : CCOP - Michigan Cancer Research Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University Of Michigan Health System

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Ann Arbor : University of Michigan

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Battle Creek : Battle Creek Health System Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bay City : Michigan State University/Bay Regional Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Bay City : Bay Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Big Rapids : Mecosta County Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit : Karmanos Cancer Institute

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Detroit : Karmanos Cancer Institute

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Detroit :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Detroit :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Detroit : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Detroit : Henry Ford Health System

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Detroit : Barbara Ann Karmanos Cancer Institute

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Detroit : Josephine Ford Cancer Center at Henry Ford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Escanaba : Green Bay Oncology, Limited - Escanaba

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Michigan State University/McLaren Regional Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Flint : Genesys Hurley Cancer Institute

Connect® MM- The Multiple Myeloma Disease Registry

Flint : Genesys Hurley Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Hurley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Singh and Arora Hematology Oncology, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : McLaren Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Grand Rapids Clinical Oncology Program

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Grand Rapids : Butterworth Hospital at Spectrum Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : CCOP - Grand Rapids

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iron Mountain : Dickinson County Healthcare System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Foote Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : West Michigan Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Kalamazoo : West Michigan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Bronson Methodist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Borgess Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Michigan State University/Breslin Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Lansing : Breslin Cancer Center at Ingham Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Sparrow Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lapeer : Michigan State University/Lapeer Regional Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Lapeer : Great Lakes Cancer Institute - Lapeer Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Livonia : St. Mary Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Community Cancer Center of Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Mercy Memorial Hospital - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Clemens : Michigan State University/Mount Clemens Regional Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Mount Clemens : Clemens Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muskegon : Mercy General Health Partners

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Novi : Newland Medical Associates

Connect® MM- The Multiple Myeloma Disease Registry

Owosso : Michigan State University/Memorial Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Petoskey : Northern Michigan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pontiac : St. Joseph Mercy Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port Huron : Mercy Regional Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Reed City : Spectrum Health Reed City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Royal Oak : William Beaumont Hospital - Royal Oak Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Southfield : Newland Medical Associates

Connect® MM- The Multiple Myeloma Disease Registry

Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Lakeside Cancer Specialists, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Lakeland Regional Cancer Care Center - St. Joseph

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Traverse City : Munson Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Warren : St. John Macomb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wyoming : Metro Health Cancer Care Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Brainerd : St. Joseph's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burnsville : Fairview Ridges Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Duluth Clinic Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Duluth : Duluth Clinic Cancer Center - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Miller - Dwan Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : CCOP - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edina : Fairview Southdale Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fridley : Mercy and Unity Cancer Center at Unity Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hutchinson : Hutchinson Area Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : HealthEast Cancer Care at St. John's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : Minnesota Oncology - Maplewood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Minnesota Oncology Hematology P.A.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Minneapolis : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Minneapolis : Hennepin County Medical Center - Minneapolis

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

New Ulm : New Ulm Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rochester : Mayo Clinic

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Rochester : Mayo Clinic - Rochester Mayo 3

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Rochester : Mayo Clinic Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Rochester : The Mayo Clinic

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Rochester : Mayo Clinic

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Saint Paul : United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shakopee : St. Francis Cancer Center at St. Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis Park : Park Nicollet Institute - Louisiana Ave.

Connect® MM- The Multiple Myeloma Disease Registry

St. Louis Park : Metro MN CCOP Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

St. Louis Park : CCOP - Metro-Minnesota

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis Park : Park Nicollet Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Paul : Regions Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Stillwater : Lakeview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waconia : Ridgeview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Willmar : Willmar Cancer Center at Rice Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Woodbury :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Woodbury : Minnesota Oncology - Woodbury

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Jackson : Jackson Oncology Associates

Connect® MM- The Multiple Myeloma Disease Registry

Jackson : Veterans Affairs Medical Center - Jackson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : University of Mississippi Cancer Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pascagoula : Regional Cancer Center at Singing River Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Cape Girardeau : Saint Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cape Girardeau : Southeast Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chesterfield : St. Louis Cancer Care, LLP

Connect® MM- The Multiple Myeloma Disease Registry

Columbia :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Jefferson City : Capitol Comprehensive Cancer Care Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Jefferson City : Columbia Comprehensive Cancer Care Clinic

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Jefferson City : Goldschmidt Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Kansas City : Kansas City Cancer Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Kansas City : Heartland Hematology Oncology Associates, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Research Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : North Kansas City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Veterans Affairs Medical Center - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Kansas City VA Medical Center

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Lee's Summit : Saint Luke's East - Lee's Summit

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberty : Parvin Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : St. John's Medical Research Institute

Connect® MM- The Multiple Myeloma Disease Registry

Springfield : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Springfield : Mercy Medical Research Institute

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Springfield : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Springfield : Mercy Medical Research Institute

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

St. Joseph : St. Joseph Oncology

Connect® MM- The Multiple Myeloma Disease Registry

St. Joseph : Saint Joseph Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Heartland Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

St. Louis : Washington University School of Medicine

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

St. Louis : University Hematology Oncology, Inc.

Connect® MM- The Multiple Myeloma Disease Registry

St. Louis : St. John's Mercy Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

St. Louis : Hematology Oncology Consultants, Inc

Connect® MM- The Multiple Myeloma Disease Registry

St. Louis : Washington University in St. Louis, Division of Oncology, Section of Bone Marrow Transplantation & Leukemia

Connect® MM- The Multiple Myeloma Disease Registry

St. Louis : Washington University School of Medicine Division of Oncology

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

St. Louis : Investigational Site Number 840002

Phase 1 SAR650984 Combination With Lenalidomide

St. Louis : Washington University School Of Medicine

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

St. Louis : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

St. Louis : David C. Pratt Cancer Center at St. John's Mercy

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Saint Louis University Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Missouri Baptist Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : CCOP - St. Louis-Cape Girardeau

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Midwest Hematology Oncology Group, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Christian Hospital Northeast Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

St. Louis : Washington University School of Medicine

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

St. Louis : Washington University School Of Medicine

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

St. Louis :

Study of KB004 in Subjects With Hematologic Malignancies

St. Louis : Washington University School of Medicine

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Billings : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Billings : Billings Clinic Updated

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Billings : CCOP - Montana Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Hematology-Oncology Centers of the Northern Rockies - Billings

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Billings Clinic - Downtown

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : St. Vincent Healthcare Cancer Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Bozeman : Bozeman Deaconess Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Butte : St. James Healthcare Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Big Sky Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Sletten Cancer Institute at Benefis Healthcare

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Helena : St. Peter's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Medical Oncology at KRMC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Institute Foundation

Connect® MM- The Multiple Myeloma Disease Registry

Missoula : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Specialists at Montana Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC

Connect® MM- The Multiple Myeloma Disease Registry

Lincoln : Nebraska Hematology Oncology, PC

Connect® MM- The Multiple Myeloma Disease Registry

Lincoln : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Lincoln : Cancer Resource Center - Lincoln

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Omaha : Missouri Valley Cancer Consortium Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Omaha : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Omaha : Immanuel Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Lakeside Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : CCOP - Missouri Valley Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Creighton University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Henderson : TORI - Comprehensive Cancer Centers of NV

Connect® MM- The Multiple Myeloma Disease Registry

Las Vegas :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Las Vegas : Southern Nevada Cancer Research Foundation

Connect® MM- The Multiple Myeloma Disease Registry

Las Vegas : University Medical Center of Southern Nevada

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : CCOP - Nevada Cancer Research Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : Nevada Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

North Las Vegas : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Reno : VA Sierra Nevada Healthcare System

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Lebanon : Dartmouth Hitchcock Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Lebanon : Dartmouth Hitchcock Medical Center

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Portsmouth : Portsmouth Regional Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

Jersey City : CarePoint Health Research Institute

Multiple Myeloma Study

View More »

Belleville : Essex Oncology of North Jersey, PA

Connect® MM- The Multiple Myeloma Disease Registry

Cherry Hill : The Center for Cancer and Hematologic Disease

Connect® MM- The Multiple Myeloma Disease Registry

Englewood : Drs. Forte, Schleider, Attas & Condemi, PA

Connect® MM- The Multiple Myeloma Disease Registry

Hackensack : HUMC

A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Hackensack : Hackensack University Medical Center

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Hackensack : Hackensack University Medical Center

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Hackensack : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hackensack : John Theurer Cancer Center at Hackensack University Medical Center

Escalating Doses Thalidomide+Bortezomib+HIgh Dose Melphalan for Auto PBSC Transplant in Patients With Multiple Myeloma

Hackensack : Hackensack University Medical Center Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Hackensack : John Theurer Cancer Center at Hackensack University

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Hackensack : Hackensack University Medical Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Hackensack : Hackensack University Medical Center

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Hackensack : John Theurer Cancer Center

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Hackensack : John Theurer Cancer Center-Hackensack University Medical Center

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function

Hackensack : Hackensack University Medical Center

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Hackensack : John Theurer Cancer Center at Hackensack University

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Hackensack : John Theurer Cancer Center - Hackensack University

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Jersey City : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Morristown : Hematology-Oncology Associates of Northern NJ dba Carol G. Simon

Connect® MM- The Multiple Myeloma Disease Registry

Morristown : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Newark : UMDNJ University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Somerville : Steeplechase Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Albuquerque : University of New Mexico Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : Hematology Oncology Associates, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Phase 2 Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Multiple Myeloma Undergoing Limited Re-infusion of CD34+ Cells

Various Cities : Millennium Pharmaceuticals

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Albany : New York Oncology Hematology, P.C.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Albany : US Oncology - Albany Medical Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Albany : US Oncology - New York Oncology Hematology, PC-Albany

Connect® MM- The Multiple Myeloma Disease Registry

Amsterdam : US Oncology - Amsterdam Community Cancer Program

Connect® MM- The Multiple Myeloma Disease Registry

Bronx : Bronx River Medical Associates

Connect® MM- The Multiple Myeloma Disease Registry

Bronx : Eastchester Center for Cancer Care

Connect® MM- The Multiple Myeloma Disease Registry

Bronx : Montefiore Medical Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Bronx : Montefiore Medical Center

Study of Intravenous Busulfan in Combination With Melphalan and Bortezomib in Patients With Multiple Myeloma

Buffalo : Roswell Park Cancer Institute

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Buffalo : Jonah Cancer Care Center & ECMC

Connect® MM- The Multiple Myeloma Disease Registry

Buffalo : Roswell Park Cancer Institute

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

East Syracuse : CCOP - Hematology-Oncology Associates of Central New York

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elmira : Falck Cancer Center at Arnot Ogden Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hudson : US Oncology - Cavell Cancer Treatment Program

Connect® MM- The Multiple Myeloma Disease Registry

Johnson City : Broome Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Lake Success : Arena Oncology Associates, PC

Connect® MM- The Multiple Myeloma Disease Registry

Lake Success : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Latham : US Oncology - New York Oncology Hematology, PC-Latham

Connect® MM- The Multiple Myeloma Disease Registry

New Hyde Park : Long Island Jewish medical Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New York : Columbia University Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

New York : Weill Medical College of Cornell University

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

New York : Columbia University

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

New York : Mount Sinai Medical Center

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

New York :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

New York :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

New York : NYU Cancer Institute

A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma

New York : Memorial Sloan-Kettering Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New York : Weill Medical College of Cornell

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

New York : Memorial Sloan Kettering Cancer Center

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

New York : New York University Langone Medical Center

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

New York : Memorial Sloan-Kettering Cancer Center

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

New York : Memorial Sloan-Kettering Cancer Center

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

New York : Memorial Sloane Kettering Cancer Center

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

New York : Weill Cornell Medicial College

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

New York : Weill Cornell Medical College

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

New York : Mount Sinai School of Medicine

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

New York : Memorial Sloan-Kettering Cancer Center

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

New York : Mount Sinai Medical Center

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

New York : Memorial Sloan-Kettering Cancer Center

Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

New York : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

New York : Columbia University Medical Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

New York : Weil Cornell Medical College - New York-Presbyterian Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

New York : Memorial Sloan-Kettering Cancer Center

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma

New York : Weill Medical College of Cornell University

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

New York : Mount Sinai School of Medicine

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

New York : St. Luke'S Roosevelt Hospital Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

New York : St. Luke'S-Roosevelt Hospital Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

New York : Mount Sinai School of Medicine, The Tisch Cancer Institute

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

New York : Memorial Sloan Kettering Cancer Center

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

New York : The Mount Sinai School of Medicine

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

New York : Memorial Sloan Kettering Cancer Ctr

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

New York : Mt. Sinai Medical Center

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

New York : Weill Cornell Medical College

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

New York : Mount Sinai School of Medicine

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

New York : Memorial Sloan Kettering Cancer Center

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

New York : NYU Cancer Institute

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

New York : Weill Cornell Medical College

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Rexford : US Oncology - New York Oncology Hematology, PC-Rexford

Connect® MM- The Multiple Myeloma Disease Registry

Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Stony Brook : Stony Brook University Hospital

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Stony Brook : Stony Brook University Medical Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Syracuse : SUNY Upstate Medical University - Adult Program

Connect® MM- The Multiple Myeloma Disease Registry

Troy : US Oncology - Troy Cancer Treatment Program

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Asheville : Mission Hospitals - Memorial Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cary : US Oncology - Cancer Centers of North Carolina - Cary

Connect® MM- The Multiple Myeloma Disease Registry

Cary : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Chapel Hill : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Chapel Hill : UNC Lineberger Comprehensive Cancer Center

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Chapel Hill : University of North Carolina at Chapel Hill

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Chapel Hill : UNC Lineberger Comprehensive Cancer Center

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Charlotte : Carolinas Medical Center

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Charlotte : Mecklenburg Medical Group

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Charlotte : Presbyterian Cancer Center at Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Durham : Duke University Medical Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Durham : DUMC Division of Cellular Therapy/ABMT

Connect® MM- The Multiple Myeloma Disease Registry

Durham : Duke University

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Durham : Duke University Medical Center

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Durham : Duke University Medical Center

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Fayetteville : Blood and Cancer Clinic

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Fayetteville : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Gastonia : Local Institution

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Goldsboro : Southeastern Medical Oncology Center

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Goldsboro : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Goldsboro : Wayne Memorial Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hendersonville : Pardee Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hickory : Carolina Oncology Specialists, PA

Connect® MM- The Multiple Myeloma Disease Registry

High Point : Emerywood Hematology/Oncology

Connect® MM- The Multiple Myeloma Disease Registry

High Point : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kinston : Kinston Medical Specialists Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Raleigh : US Oncology - Cancer Centers of North Carolina - Falls

Connect® MM- The Multiple Myeloma Disease Registry

Rutherfordton : Rutherford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Statesville : Iredell Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Winston-Salem : Piedmont Hematology Oncology Associates, Pa

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Bismarck : Mid Dakota Clinic, Pc

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Bismarck : Legacy Pharma Research

Connect® MM- The Multiple Myeloma Disease Registry

Bismarck : Med Center One

Connect® MM- The Multiple Myeloma Disease Registry

Bismarck : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Fargo : Roger Maris Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Akron : Summa Health System - Cancer Research Office

Connect® MM- The Multiple Myeloma Disease Registry

Akron : McDowell Cancer Center at Akron General Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bowling Green : Wood County Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Canton : Gabrail Cancer Center Research

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Canton : Gabrail Cancer Center Research

Connect® MM- The Multiple Myeloma Disease Registry

Canton : Gabrail Cancer Center Research Updated

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Canton : Gabrail Cancer Center Research

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Canton : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Canton : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Chillicothe : Adena Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinnati : Christ Hospital Cancer Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Cincinnati : Oncology Hematology Care Inc.

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Cincinnati : Charles M. Barrett Cancer Center at University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cleveland : University Hospitals Seidman Cancer Center Updated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Cleveland : University Hospitals Case Medical Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Cleveland : Cleveland VA Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Cleveland : Cleveland Clinic

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Cleveland : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Cleveland : Cleveland Clinic, Taussig Cancer Institute

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Cleveland : Cleveland Clinic-Taussig Cancer Center

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function

Columbus : OSU

A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Columbus : The Ohio State University Medical Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Columbus : Mid Ohio Oncology/Hematology, Inc

Connect® MM- The Multiple Myeloma Disease Registry

Columbus : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Columbus : Benson, Md, Don

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Columbus : Grant Medical Center Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Riverside Methodist Hospital Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Mount Carmel Health - West Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : CCOP - Columbus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Doctors Hospital at Ohio Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Ohio State University

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Dayton : David L. Rike Cancer Center at Miami Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : CCOP - Dayton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Grandview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Samaritan North Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Delaware : Grady Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Hematology Oncology Center, Inc

Connect® MM- The Multiple Myeloma Disease Registry

Elyria : Hematology Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Community Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Findlay : Blanchard Valley Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Franklin : Middletown Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Wayne Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kettering : Charles F. Kettering Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kettering :

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Lancaster : Fairfield Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lima : Lima Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Strecker Cancer Center at Marietta Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maumee : Northwest Ohio Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Knox Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : Toledo Clinic - Oregon

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : St. Charles Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portsmouth : Southern Ohio Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Community Hospital of Springfield and Clark County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sylvania : Flower Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tiffin : Mercy Hospital of Tiffin

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Vincent Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Anne Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : CCOP - Toledo Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Clinic, Incorporated - Main Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Medical University of Ohio Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy : UVMC Cancer Care Center at Upper Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wauseon : Fulton County Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westerville : Mount Carmel St. Ann's Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wooster : Lawrence M. Stallings MD LTD dba Trilogy Cancer Care

Connect® MM- The Multiple Myeloma Disease Registry

Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zanesville : Genesis - Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Oklahoma City : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Tulsa : Cancer Care Associates

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Tulsa : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Clackamas : Clackamas Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coos Bay : Bay Area Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Eugene : Willamette Valley Cancer and Research / USOR

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene

Connect® MM- The Multiple Myeloma Disease Registry

Grants Pass : Three Rivers Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gresham : Legacy Mount Hood Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Dubs Cancer Center at Rogue Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Providence Cancer Center at PMCC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukie : Providence Milwaukie Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newberg : Providence Newberg Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon City : Willamette Falls Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Oregon Health & Science University

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : CCOP - Columbia River Oncology Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence Cancer Center at Providence Portland Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence St. Vincent Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Oregon Health Science University

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Springfield : Willamette Valley Cancer Institute and Research Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield

Connect® MM- The Multiple Myeloma Disease Registry

Springfield :

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Tualatin : Northwest Cancer Specialists, P.C.

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Tualatin : Legacy Meridian Park Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bethlehem : Oncology Hematology of Lehigh Valley

Connect® MM- The Multiple Myeloma Disease Registry

Danville : Geisinger Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Drexel Hill : Consultants in Medical Oncology and Hematology, PC

Connect® MM- The Multiple Myeloma Disease Registry

Harrisburg : Andrews and Patel Associates

Connect® MM- The Multiple Myeloma Disease Registry

Kingston : US Oncology - Medical Oncology Associates (Nahar)

Connect® MM- The Multiple Myeloma Disease Registry

Kittanning :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Lancaster : Lancaster Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Philadelphia : Fox Chase Cancer Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Philadelphia : University of Pennsylvania Abramson Cancer Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Philadelphia : Fox Chase Cancer Center

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Philadelphia :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Philadelphia : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Philadelphia : University of Pennsylvania Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Philadelphia : Fox Chase Cancer Center

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Philadelphia : Fox Chase Cancer Center

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Philadelphia : Albert Einstein Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Philadelphia : Fox Chase Cancer Center

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Philadelphia : Abramson Cancer Center Of The University Of Pennsylvania

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

Philadelphia : University of Pennsylvania

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Philadelphia : Hospital of the University of Pennsylvania

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Pittsburgh : The Western Pennsylvania Hospital

Connect® MM- The Multiple Myeloma Disease Registry

Pittsburgh : UPCI Hillman Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Pittsburgh : Pittsburgh VA Medical Center

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Reading : Berks Hematology Oncology Associates

Connect® MM- The Multiple Myeloma Disease Registry

Scranton : Scranton Hematology Oncology

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

West Reading : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

West Reading : Reading Hospital and Medical Center Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Cranston : Hematology & Oncology Associates of Rhode Island

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Anderson : AnMed Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston : MUSC Hollings Cancer Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Charleston : Medical University of South Carolina Hollings Cancer Center

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Charleston : Charleston Hematology Oncology Associates, PA

Connect® MM- The Multiple Myeloma Disease Registry

Charleston : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Charleston : Charleston Hematology Oncology Associates, Pa

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Charleston : Medical University of South Carolina

Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

Charleston : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Charleston : Hollings Cancer Center at Medical University of South Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbia : South Carolina Oncology Associates

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Easley : US Oncology - Cancer Centers of the Carolinas - Easley

Connect® MM- The Multiple Myeloma Disease Registry

Easley : Cancer Centers of the Carolinas - Easley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Greenville : Saint Francis Hospital

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut

Connect® MM- The Multiple Myeloma Disease Registry

Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris

Connect® MM- The Multiple Myeloma Disease Registry

Greenville : US Oncology - Cancer Centers of the Carolinas - Eastside

Connect® MM- The Multiple Myeloma Disease Registry

Greenville : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Greenville : Cancer Center of the Carolinas

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Greenville : Greenville Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Grove Commons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : CCOP - Greenville

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Bon Secours St. Francis Health System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Faris Road

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Eastside

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville :

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Greenwood : Self Regional Cancer Center at Self Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hilton Head Island : SC Cancer Specialists, PA

Connect® MM- The Multiple Myeloma Disease Registry

Seneca : US Oncology - Cancer Center of the Carolinas - Seneca

Connect® MM- The Multiple Myeloma Disease Registry

Seneca : Cancer Centers of the Carolinas - Seneca

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg

Connect® MM- The Multiple Myeloma Disease Registry

Spartanburg : Cancer Centers of the Carolinas - Spartanburg

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : CCOP - Upstate Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Sioux Falls : Avera Cancer Institute

Connect® MM- The Multiple Myeloma Disease Registry

Sioux Falls : Sanford Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Sioux Falls : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux Falls : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Chattanooga : Chattanooga Oncology Hematology Associates

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Collierville : Family Cancer Center, PLLC

Connect® MM- The Multiple Myeloma Disease Registry

Cookeville : Cookeville Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Germantown : Jones Clinic

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Knoxville : Tennessee Cancer Specialists

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Memphis : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Memphis : Family Cancer Center Foundation, Inc.

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Nashville :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Nashville :

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Nashville : Sarah Cannon Research Institute

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Nashville : SCRI

Connect® MM- The Multiple Myeloma Disease Registry

Nashville : Tennessee Oncology, PLLC

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Nashville : The Vanderbilt Clinic

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Nashville : Sarah Cannon Research Institute

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma

Nashville : Tennessee Oncology

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Nashville : Tennessee Oncology, Pllc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Nashville : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Nashville : Sarah Cannon Research Institute

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Nashville : Sarah Cannon Research Institute

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Nashville : Sarah Cannon Research Institute Tennessee Oncology Drug Development Unit

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Nashville : Sarah Cannon Research Institute

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Nashville : Tennessee Oncology

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Nashville : Sarah Cannon Research Institute (SCRI) Drug Development Unit

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Nashville : Sarah Cannon Research Institute (SCRI)

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Abilene : US Oncology - Texas Cancer Center - Abilene (South)

Connect® MM- The Multiple Myeloma Disease Registry

Amarillo :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Amarillo : US Oncology - Texas Oncology, PA - Amarillo

Connect® MM- The Multiple Myeloma Disease Registry

Amarillo : Texas Oncology

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Amarillo : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Amarillo : Harrington Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Arlington : US Oncology - Texas Oncology - Arlington South

Connect® MM- The Multiple Myeloma Disease Registry

Austin :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Austin : US Oncology - Texas Oncology - Midtown

Connect® MM- The Multiple Myeloma Disease Registry

Austin : US Oncology - Texas Oncology Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Austin : Austin Cancer Centers

Connect® MM- The Multiple Myeloma Disease Registry

Austin : US Oncology - Southwest Regional Cancer Center - North

Connect® MM- The Multiple Myeloma Disease Registry

Austin : US Oncology - Texas Oncology North Austin

Connect® MM- The Multiple Myeloma Disease Registry

Austin : US Oncology - South Austin Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Bedford : Texas Oncology - Bedford

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Bedford : US Oncology - Texas Oncology, PA - Bedford

Connect® MM- The Multiple Myeloma Disease Registry

Bryan : St. Joseph Regional Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Cedar Park : US Oncology - Texas Oncology Cedar Park

Connect® MM- The Multiple Myeloma Disease Registry

College Station : Scott & White Clinic

Connect® MM- The Multiple Myeloma Disease Registry

Corpus Christi : South Texas Institute of Cancer

Connect® MM- The Multiple Myeloma Disease Registry

Corpus Christi : Coastal Bend Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Corpus Christi : Cancer Specialists Of South Texas, Pa

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Dallas :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Dallas : Baylor Charles A. Sammons Cancer Center at Dallas

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Dallas : Texas Oncology - Medical City Dallas

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Dallas : Texas Oncology - Dallas Presbyterian

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Dallas : US Oncology -Texas Oncology, PA - Dallas

Connect® MM- The Multiple Myeloma Disease Registry

Dallas : US Oncology - Texas Cancer Center at Medical City

Connect® MM- The Multiple Myeloma Disease Registry

Dallas : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Dallas : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Dallas : Mary Crowley Cancer Research Centers

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Denton :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

El Paso : US Oncology - El Paso Cancer Treatment Ctr

Connect® MM- The Multiple Myeloma Disease Registry

Fort Sam Houston : San Antonio Military Medical Center (SAMMC)

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Fort Sam Houston : Brooke Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Sam Houston : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Fort Worth : Texas Oncology - Fort Worth 12th Avenue

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Fort Worth : US Oncology - Southwest Forth Worth Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Fort Worth : US Oncology - Texas Oncology, PA - Forth Worth

Connect® MM- The Multiple Myeloma Disease Registry

Galveston : University of Texas Medical Branch

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Garland : US Oncology - Texas Oncology, PA - Garland

Connect® MM- The Multiple Myeloma Disease Registry

Garland : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Grapevine : US Oncology - Texas Oncology - Grapevine

Connect® MM- The Multiple Myeloma Disease Registry

Houston : MD Anderson Cancer Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Houston : MD Anderson Cancer Center

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Houston : MD Anderson Center

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Houston : MD Anderson Cancer Center/University of Texas Dept.ofMDAndersonCancerCtr(SC)

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Houston :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Houston : MD Anderson Cancer Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Houston : MD Anderson Cancer and Research Center

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Houston : UT MD Anderson Cancer Center

Arry-520 + Carfilzomib for Multiple Myeloma (MM)

Houston : MD Anderson Cancer Center / University of Texas

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Houston : UT MD Anderson Cancer Center

Busulfan Plus Melphalan Versus Melphalan

Houston : UT MD Anderson Cancer Center

Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

Houston : UT MD Anderson Cancer Center

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Houston : The Methodist Hospital Research Institute-AOCT

Connect® MM- The Multiple Myeloma Disease Registry

Houston : MD Anderson Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Houston : U T M D Anderson Cancer Center

Dose-escalation Study of Oral CX-4945

Houston : UT MD Anderson Cancer Center

MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients

Houston : University of Texas MD Anderson Cancer Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Houston : The Methodist Cancer Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Houston : The University Of Texas Md Anderson Cancer Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Houston : Northwest Cancer Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Houston : M. D. Anderson Cancer Center at University of Texas

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Veterans Affairs Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Ben Taub General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Baylor University Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Houston : MD Anderson Cancer Center

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Houston : Northwest Cancer Center

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Houston :

Study of KB004 in Subjects With Hematologic Malignancies

Houston : MD Anderson

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function

Houston : Houston VA Medical Center

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Irving : Southlake Oncology dba Las Colinas Hematology Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville

Connect® MM- The Multiple Myeloma Disease Registry

Kyle : US Oncology - Texas Oncology - Kyle

Connect® MM- The Multiple Myeloma Disease Registry

Longview : US Oncology - Longview Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Lubbock : Joe Arrington Cancer Research and Treatment Center

Connect® MM- The Multiple Myeloma Disease Registry

McAllen :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Midland : US Oncology - Allison Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Odessa : US Oncology - Texas Oncology - Odessa

Connect® MM- The Multiple Myeloma Disease Registry

Plano : US Oncology - North Texas Regional Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Plano : US Oncology - Texas Oncology Plano West Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Round Rock : Texas Oncology - Central Austin Cancer Center

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Round Rock : US Oncology - Texas Oncology Seton Williamson

Connect® MM- The Multiple Myeloma Disease Registry

Round Rock : US Oncology - Texas Oncology - Round Rock Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

San Antonio : University of Texas Health Science Center

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak

Connect® MM- The Multiple Myeloma Disease Registry

San Antonio : US Oncology - Cancer Care Centers of South Texas

Connect® MM- The Multiple Myeloma Disease Registry

San Antonio : US Oncology - HOAST - Medical Dr.

Connect® MM- The Multiple Myeloma Disease Registry

San Antonio : South Texas Accelerated Research Therapeutics

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

San Antonio : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

San Antonio : University Hospital - San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : University of Texas Health Science Center at San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Cancer Therapy and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : South Texas Accelerated Research Therapeutics, LLC (START)

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

San Antonio : Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

San Marcos : US Oncology - Texas Oncology - San Marcos

Connect® MM- The Multiple Myeloma Disease Registry

Sherman : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Temple : Scott & White Healthcare Department of Research

Connect® MM- The Multiple Myeloma Disease Registry

Temple : Scott & White Healthcare

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Temple : CCOP - Scott and White Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tyler :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Tyler : ETMC dba Blood and Cancer Center - East Texas

Connect® MM- The Multiple Myeloma Disease Registry

Tyler : ETMC dba Tyler Hematology Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Waco : Texas Oncology - Waco

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Waco : US Oncology - Texas Oncology Cancer Care and Research Center

Connect® MM- The Multiple Myeloma Disease Registry

Wichita Falls : US Oncology - Texoma Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

American Fork : Central Utah Clinic

Connect® MM- The Multiple Myeloma Disease Registry

American Fork : American Fork Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar City : Sandra L. Maxwell Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Logan : Logan Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ogden : Northern Utah Associates

Connect® MM- The Multiple Myeloma Disease Registry

Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Provo : Utah Valley Regional Medical Center - Provo

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Salt Lake City : University of Utah - Huntsman Cancer Institute

Connect® MM- The Multiple Myeloma Disease Registry

Salt Lake City : Huntsman Cancer Institute

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Salt Lake City : University of Utah School of Medicine

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Salt Lake City : Huntsman Cancer Institute

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Salt Lake City : Huntsman Cancer Institute at University of Utah

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : LDS Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Utah Cancer Specialists at UCS Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Huntsman Cancer Institute At The Univ. Of Utah

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

St. George : Dixie Regional Medical Center - East Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Arlington : US Oncology - Arlington Fairfax Hematology Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Christiansburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Christiansburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Fairfax : Virginia Cancer Specialists, PC

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Fairfax : US Oncology - Fairfax-Northern VA Hem-Onc PC

Connect® MM- The Multiple Myeloma Disease Registry

Fairfax : Virginia Cancer Specialists

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Fredericksburg : Hematology-Oncology Associates Of Fredricksburg, Inc

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Fredericksburg : Fredericksburg Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gainesville : US Oncology - Fairfax Northern Virginia Hematology-Oncology, PC-Gainesville

Connect® MM- The Multiple Myeloma Disease Registry

Leesburg : US Oncology - Fairfax-Northern Virgina Hem-Onc, PC-Leesburg

Connect® MM- The Multiple Myeloma Disease Registry

Newport News : Peninsula Cancer Institute

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Norfolk :

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Richmond : Virginia Commonwealth University

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

Richmond : Virginia Commonwealth University

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Richmond : Massey Cancer Center/Virginia Commonwealth University

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Winchester : US Oncology - Shenandoah Oncology - Winchester

Connect® MM- The Multiple Myeloma Disease Registry

Woodbridge : US Oncology - Fairfax-Northern Virginia Hem-Onc, PC-Woodbridge

Connect® MM- The Multiple Myeloma Disease Registry

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Anacortes : Island Hospital Cancer Care Center at Island Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bellingham : Peace Health Medical Group

Connect® MM- The Multiple Myeloma Disease Registry

Bellingham : St. Joseph Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bremerton : Olympic Hematology and Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burien : Highline Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Centralia : Providence Centralia Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edmonds : Puget Sound Cancer Centers

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Edmonds : US Oncology - Puget Sound Cancer Center-Edmonds

Connect® MM- The Multiple Myeloma Disease Registry

Everett : Providence Everett Medical Center

Connect® MM- The Multiple Myeloma Disease Registry

Everett : Providence Regional Cancer Partnership

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Federal Way : St. Francis Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Issaquah : Swedish Medical Center - Issaquah Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kennewick : Columbia Basin Hematology and Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Kennewick : Columbia Basin Hematology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Skagit Valley Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Olympia : Providence St. Peter Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Harrison Poulsbo Hematology and Onocology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Puyallup : Good Samaritan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Seattle : Fred Hutchinson Cancer Research Center

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Seattle : Fred Hutchinson Cancer Research Center

A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma

Seattle : Fred Hutchinson Cancer Research Center

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Seattle : University Of Washington School Of Medicine

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Seattle : US Oncology - Puget Sound Cancer Center-Seattle

Connect® MM- The Multiple Myeloma Disease Registry

Seattle : Fred Hutchinson Cancer Research Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Seattle : Virginia Mason Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Pacific Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Harborview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : CCOP - Virginia Mason Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Minor and James Medical, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Polyclinic First Hill

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : University Cancer Center at University of Washington Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Group Health Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research Institute

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Sedro-Woolley : North Puget Oncology at United General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Spokane : Medical Oncology Associates PS

Connect® MM- The Multiple Myeloma Disease Registry

Spokane : US Oncology - Cancer Care Northwest - Sherman

Connect® MM- The Multiple Myeloma Disease Registry

Spokane : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Spokane : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Spokane : Evergreen Hematology and Oncology, PS

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Cancer Care Northwest - Spokane South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane Valley : Cancer Care Northwest

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Tacoma : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Tacoma : St. Clare Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : CCOP - Northwest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Allenmore Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Franciscan Cancer Center at St. Joseph Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Southwest Washington Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Legacy Salmon Creek Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walla Walla : Providence St. Mary Regional Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Wenatchee : Wenatchee Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Yakima :

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Yakima :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Yakima : Yakima Valley Memorial Hospital/ North Star Lodge

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Yakima : Yakima Regional Cancer Care

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Yakima : Yakima Valley Memorial Hospital / North Star Lodge

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge

Connect® MM- The Multiple Myeloma Disease Registry

Yakima : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Yakima :

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

Morgantown : West Virginia University - Clinical Trials Research Unit

BMTCTN0702 - A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma.

Morgantown : West Virginia University - Clinical Trials Research Unit

C16006- An Open-Label, Dose Escalation

Morgantown : West Virginia University - Clinical Trials Research Unit

C16010 A Phase 3, Double-blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone

Morgantown : West Virginia University - Clinical Trials Research Unit

CC-4047-MM-009 A Multicenter, Single-Arm, Open-Label Treatment Use Program For Pomalidomide (POM)

Morgantown : West Virginia University - Clinical Trials Research Unit

PRE1003 A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone

Morgantown : West Virginia University - Clinical Trials Research Unit

SNS01-T-001 - Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma

View More »

Huntington : Edwards Comprehensive Cancer Center

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Morgantown : West Virginia University

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Morgantown : West Virginia University - Clinical Trials Research Unit

Connect® MM- The Multiple Myeloma Disease Registry

Morgantown : WVU Mary Babb Randolph Cancer Center Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Morgantown : West Virginia University Mary Babb Randolf Cancer Center

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Morgantown : Mary Babb Randolph Cancer Center/WVU

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Appleton : Fox Valley Hematology & Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Green Bay : St. Vincent Hospital/Green Bay Oncology

Connect® MM- The Multiple Myeloma Disease Registry

Green Bay : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Mary's Hospital Medical Center - Green Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Crosse : Gundersen Lutheran Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

La Crosse : Gundersen Clinic, Ltd

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

La Crosse : Gundersen Lutheran Center for Cancer and Blood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Madison : University of Wisconsin

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Madison : Dean Clinic-Hematology And Oncology

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Madison : Celgene Study Site

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Manitowoc : Holy Family Memorial Medical Center Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukee : Medical College of Wisconsin

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Milwaukee : Froedtert & Medical College of Wisconsin-CLCC

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Milwaukee : CMS Water Tower Medical Commons Medical Oncology #100

Connect® MM- The Multiple Myeloma Disease Registry

Milwaukee : Medical College of Wisconsin/Froedtert Hospital

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Milwaukee : Medical College of Wisconsin - Clinical Cancer Center

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Minocqua : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Oconto Falls : Green Bay Oncology, Limited - Oconto Falls

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sheboygan : St. Nicholas Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waukesha : Waukesha Memorial Hospital

Connect® MM- The Multiple Myeloma Disease Registry

Waukesha : Waukesha Memorial Hospital (ProHealth Care) Updated

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Additional Locations : Millennium Pharmaceuticals Updated

An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma

View More »

Casper : Rocky Mountain Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Adelaide : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Adelaide :

Study of KB004 in Subjects With Hematologic Malignancies

Adelaide :

Velcade (Bortezomib) Consolidation After Transplant

Box Hill : Box Hill Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Brisbane : Mater Adult Hospital

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

View More »

Camperdown :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Camperdown :

Velcade (Bortezomib) Consolidation After Transplant

Canberra : The Canberra Hospital

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Canberra : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Clayton : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Darlinghurst : St. Vincent's Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Douglas : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

East Melbourne :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

East Melbourne : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Epping : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Fitzroy : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Footscray : Western Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Frankston : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Geelong : Barwon Health

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Geelong :

Velcade (Bortezomib) Consolidation After Transplant

Greenslopes :

Velcade (Bortezomib) Consolidation After Transplant

Harston : Royal Brisbane and Women's Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Heidelberg :

Velcade (Bortezomib) Consolidation After Transplant

Heidelberg Melbourne : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Herston : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Herston :

Velcade (Bortezomib) Consolidation After Transplant

Hobart : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Liverpool : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Malvern :

Velcade (Bortezomib) Consolidation After Transplant

Melbourne : Peter MacCallum Cancer Centre

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Melbourne : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Melbourne : The Alfred Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Nedlands : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Nedlands :

Velcade (Bortezomib) Consolidation After Transplant

Newcastle :

Velcade (Bortezomib) Consolidation After Transplant

Nsw 2298 : Calvary Mater Newcastle

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Parkville : Royal Melbourne Hospital

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Parkville : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Perth : Royal Perth Hospital

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Perth : Royal Perth Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Perth : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Prahran : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Prahran :

Study of KB004 in Subjects With Hematologic Malignancies

Prahran :

Velcade (Bortezomib) Consolidation After Transplant

Queensland :

Study of KB004 in Subjects With Hematologic Malignancies

Randwick :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

South Brisbane : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

South Brisbane : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Sydney :

Velcade (Bortezomib) Consolidation After Transplant

Tweed Heads : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Waratah : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Westmead : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Westmead :

Study of KB004 in Subjects With Hematologic Malignancies

Westmead N/A :

Velcade (Bortezomib) Consolidation After Transplant

Wodonga : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Woodville South : The Queen Elizabeth Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Woodville South :

Velcade (Bortezomib) Consolidation After Transplant

Woolloongabba :

Velcade (Bortezomib) Consolidation After Transplant

Graz : Medizinische Universität Graz

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Graz :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Graz : Landeskrankenhaus Graz

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Graz : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Innsbruck : Universitätsklinikum Innsbruck

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

View More »

Innsbruck :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Innsbruck : Universitätsklinik Innsbruck

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Innsbruck : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Innsbruck : Medical University Innsbruck, Division of Hematology and Oncology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Innsbruck : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Krems an der Donau : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Linz : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Rankweil : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Salzburg : Salzburger Landeskliniken

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Salzburg : Landeskrankenhaus Salzburg

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Salzburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Salzburg : University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Vienna : Wilhelminenspital, Department of Medicine I, Center of Oncology and Hematology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Wels : Klinikum Wels-Grieskirchen GmbH

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Wels : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Wien : Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

Wien : Wilhelminenspital Wien

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Wien : Allgemeines Krankenhaus Wien - Medizinische Universität Wien

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Wien : Wilhelminenspital der Stadt Wien

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Wien : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Andtwerpen : ZNA AZ Stuivenberg

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Antwerpen :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Antwerpen :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Antwerpen : Lange Beeldekensstraat

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Brussel : Universitair Ziekenhuis Brussel

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

View More »

Brussels : UZ Brussels

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Brussels : UCL Saint Luc

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Brussels :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Brussels :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Brussels : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Brussles : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Bruxelles : Institut Jules Bordet

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Bruxelles : Cliniques Universitaires Saint-Luc

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Charleroi : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Edegem-Antwerp : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Gent :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Gent :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Gent : University Hospital Gent

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Haine St Paul : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Leuven : UZ Gasthuisberg

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Leuven : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Liege : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Mons : CHU Ambroise Pare

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Roeselare : H.-Hartziekenhuis Roeselare-Menen

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Roeselare : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Yvoir : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Porto Alegre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Pleven : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Plovdiv : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Plovdiv : University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Sofia : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Sofia : Clinic of Hematology, Military Medical Academy - Sofia

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

View More »

Varna : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Barrie : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Burnaby : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Calgary : Tom Baker Cancer Centre

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Calgary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Calgary : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

View More »

Calgary : Tom Baker Cancer Centre

Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Edmonton : Cross Cancer Centre

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Edmonton : Cross Cancer Institute

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Edmonton : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Halifax : QEII Health Sciences Centre

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Halifax : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Halifax : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Laval : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

London : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Moncton : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Montréal : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Montral : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Montreal : Royal Victoria Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Montreal : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Newmarket : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ontario : London Health Sciences Centre

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ontario : The Ottawa Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Quebec : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Quebec : CHA/Québec-Hôpital Enfant-Jésus

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Saint John : Saint John Regional Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Saint John : Saint John Regional Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Saint John : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Saskatoon : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Sault Ste. Marie : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

St. Johns : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

St. John's, NL : General Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Toronto : University Health Network-Princess Margaret Hospital

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Toronto : Princess Margaret Cancer Centre

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

Toronto : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Toronto : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Toronto : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Toronto : University Health Network, Princess Margaret Hospital

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Vancouver : Vancouver General Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Vancouver : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Vancouver : Vancouver General Hospital

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Windsor : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Windsor : Windsor Regional Cancer Program

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Winnipeg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Beijing : Beijing Clinical Service Center

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Tianjin : Hematologic Hospital of Chinese Academy of Medical Sciences

Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma

Zagreb :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Brno : Fakultni nemocnice Brno

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Brno : Fakultni nemocnice Ostrava

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Brno : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Brno : Fakultni nemocnice Brno

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Brno : Fakultni nemocnice Brno

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

View More »

Hradec Kralove : Fakultni nemocnice Hradec Kralove

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Hradec Kralove : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Olomouc : Fakultni Nemocnice Olomouc

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Olomouc : Fakultni nemocnice Olomouc

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ostrava : Fakultni nemocnice Ostrava

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ostrava-Poruba : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Plzen : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Prague : Všeobecná fakultní nemocnice v Praze

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Praha : I. Interni klinika - klinika hematologie 1. LF a VFN

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Praha 10 : Fakultni Nemocnice Kralovske Vinohrady

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Praha 10 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Praha 10 : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Praha 2 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Sokolska : Fakultni nemocnice Hradec Kralove

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Srobarova : Fakultni nemocnice Kralovske Vinohrady

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Znojmo : Nemocnice Znojmo

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Copenhagen : Rigshospitalet

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Copenhagen : Rigshospitalet Clinic of Hematology L4042

Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma

Odense :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Vejle : Vejle Sygehus

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Vejle : Vejle Hospital

Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma

Tallinn N/A :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Tartu :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Helsinki : Helsinki University Hospital Hemat Dept

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Kuopio : Kuopio University Hospital

First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02

Amiens Cedex 1 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Bordeaux :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Caen :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Caen : Chru Caen

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Cedex : Institut Paoli Calmettes, Departement d'Onco-Hematologie

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

View More »

Cedex : Centre Hospitalier Lyon-Sud

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Cedex : Centre Hospitalier de lo Cote Baque

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Clermont Ferrand : CHU Estaing

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Corbeil Essonne : Centre Hospitalier Sud Francilien

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Créteil : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Dijon :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Dijon :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Dijon : CHU DIJON, Hôpital d'Enfants

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Grenoble : CHRU, Hôpital A.Michallon

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Grenoble Cedex 9 : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Le Kremlin Bicêtre : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Le Mans : CH Le Mans

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Le Mans : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Le Mans : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Le Mans Cedex 9 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Lille : Centre Hospitalier Régional Universitaire de Lille, Hôpital Huriez

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Lille : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Lille : Chru Lille

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Lille Cedex :

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Lille cedex : CHRU de Lille, Hopital Huriez

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Lille Cedex : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Limoges : Hôpital Universitaire Dupuytren

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Lyon :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Lyon : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Marseille : Hôpital Ambroise Paré

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Marseille :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Marseille : Institut Paoli Calmette,

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Marseille Cedex : Institut Paoli Calmettes

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Marseille cedex 5 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Marseille Cedex 9 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Montpellier :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Montpellier cedex 5 : Hôpital Saint Eloi

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Nantes :

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Nantes : Hôtel-Dieu

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Nantes : Hôpital de l'Hôtel Dieu

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Nantes : CHU Nantes, Hôtel-Dieu

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Nantes : CHRU, Hôtel Dieu

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Nantes : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Nantes Cedex 1 :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Nantes Cedex 1 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Nice Cedex 3 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Nimes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Paris : Hôpital Saint Antoine

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Paris : Hôpital Saint Louis

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Paris : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Paris : Hopital Saint Antoine

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Paris : Hopital Saint Louis - Service d'Immuno-Hematologie

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Paris : CHU - Hôpital St Antoine,

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Paris : Hôpital Saint-Louis

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Paris : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Paris Cedex 12 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Paris Cedex 14 : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Perpignan : Centre Hospitalier Saint Jean

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Pessac : Hôpitaux du Haut Leveque

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Pessac Cedex : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Pierre Benite : Centre Hospitalier Lyon Sud -2

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Pierre Benite : Centre Hospitalier Lyon Sud -1

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Pierre-Bénite cedex : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Reims Cedex : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Rennes : CHRU RENNES 2, Hôpital Pontchaillou

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Rennes cedex : CHU de Rennes, Hopital Pontchaillou

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Rennes cedex 9 : Hôpital Pontchaillou 2 Rue Henri le Guilloux

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Rouen : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Rouen Cedex : Centre Henri Becquerel

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Saint Herblain :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Strasbourg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Toulouse : Hopital Purpan

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Toulouse :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Toulouse : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Toulouse Cedex : Institut Claudius Régaud

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Tours :

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Tours :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Tours cedex : Hôpital Bretonneau

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Vandoeuvre : CHRU, Hôpitaux de Brabois

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Vandoeuvre Les Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Vandoeuvre Les Nancy : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Villefranche Sur Saone Cedex : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Villejuif :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Villejuif Cedex : Institut Gustave Roussy, Dept. of Medicine

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Aschaffenburg : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Aschaffenburg : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Bamberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Berlin :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Berlin : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

View More »

Berlin : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Bonn : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Chemnitz : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Chemnitz : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Dresden : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Dresden : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Essen : Universitätsklinikum Essen

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Essen : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Flensburg : Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Frankfurt : Universitätsklinik Frankfurt - Medizinische Klinik II

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Freiburg : Universitätsklinikum Freiburg, Abteilung für Innere Medizin I

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Freiburg : University Hospital Freiburg, Medizinische Universitätsklinik, Innere Medizin I, Haematologie und Onkologie

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Freiburg : University Medical Center Freiburg

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Hamburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Hamm : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Hamm : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Heidelberg : Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum, Im Neuenheimer Feld 410

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

Heidelberg :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Heidelberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Heidelberg : Universitätsklinikum Heidelberg - Medizinische Klinik V

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Heidelberg : University Hospital of Heidelberg, Department V

Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy

Heidelberg : Department of Internal Medicine V

Exploratory Study on POL6326 in Stem Cell Mobilization

Heidelberg : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Heidelberg : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Jena : Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Jena : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Köln : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kiel : Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Koeln :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Koln : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Köln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Leipzig : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Leipzig : University of Leipzig

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Lübeck : Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Münster : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Magdeburg : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Mainz : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Munchen : LMU Klinikum der Universität München - Grosshadern

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Munchen : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

München : III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Munich : Klinikum rechts der Isar/ Studien / III. Med. Klinik/ Ismaninger Str. 22

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

Munster : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Münster : University Hospital Münster, Medizinische Klinik und Poliklinik A

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Offenbach : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Oldenburg : Klinikum Oldenburg GmbH, Klinik für Innere Medizin II

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Regensburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Stuttgart : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Tubingen : Universitatsklinikum Tubingen, Medizinische Klinik und Poliklinik - Abteilung ll

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Tuebingen : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ulm : Universitätsklinikum Ulm,Klinik für Innere Medizin III

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Ulm : University Hospital Ulm, Zentrum für Innere Medizin,

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Ulm : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Villingen-Schwenningen : Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Wuerzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Würzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Oberdürrbacher Straße 6

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

Würzburg : Universitätsklinikum Würzburg - Med. Klinik und Poliklinik II

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Würzburg : University Hospital Würzburg, Hämatologie/Onkologie und Early Clinical Trial Unit (ECTU) Zentrum für Innere Medizin (ZIM)

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Ampelokipoi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Athens : General Hospital of Athens " Alexandra"

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Athens : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Athens : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

View More »

Heraklion : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ioannina : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Larissa : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Patra : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Patras : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Thessaloniki : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hong Kong : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

New Territories : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Shatin, N.T. : Department of Clinical Oncology, Prince of Wales Hospital

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Budapest : Egyesitett Szent Istvan es Szent Laszlo Korhaz

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Budapest : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Budapest : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Debrecen : Debreceni Egyetem Orvos- és Egészségtudományi Cent

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Debrecen : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

View More »

Debrecen : Debreceni Egyetem Orvos-es Egeszsegtudomanyi Centrum Belgyogyaszati Intezet

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Gyula : Pándy Kálmán Megyei Kórház

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Gyula : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kaposvar : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kaposvar : Somogy Megyei Kaposi Mor Oktato Korhaz

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Kecskemet : Bacs-Kiskun Megyei Korhaz

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Szeged : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Szeged : Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar ll. sz. Belgyogyaszati Klinika es Kardiologiai Kozpont

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Co Galway : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Co-Limerick : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Dublin : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Dublin : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Galway : GSK Investigational Site

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

View More »

Tullamore : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Afula : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ashkelon :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Ashkelon : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Haifa : Rambam Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Haifa :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

View More »

Haifa : Rambam Health Care Campus

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Jerusalem : Hadassah University Hospital Ein Kerem

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Jerusalem : Hadassah University Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Jerusalem : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Kfar Saba : Meir Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Kfar Saba :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Naharia :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Nahariya : Western Galilee Hospital - Nahariya

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Nahariya : Western Galilee Hospital Nahariya

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Nahariya : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Petach Tikva :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Petach Tikva :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Petah Tikva : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Petah-Tikva :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Ramat Gan :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Ramat Gan : Sheba MC

Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma

Rehovot : Kaplan Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Rehovot : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Tel Aviv : Tel Aviv Sourasky Medical Center

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Tel Aviv : Tel Aviv Sourasky (Ichilov) Medical Center

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Tel Aviv : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Zerifin : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ancona : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ancona : Azienda Ospedaliero-Universitaria, Clinica Ematologica

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ancona : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ancona : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Bari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

View More »

Bari : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Bergamo : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Bergamo : USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII

SST0001 in Advanced Multiple Myeloma

Bologna : Azienda Ospedaliero-Universitaria di Bologna - Pol

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Bologna : Istituto de Ematologia ed Oncologia Medica

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Bologna : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Bologna : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Bolzano : Division of Hematology and CBMT

Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs

Brescia : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Brescia : Azienda Ospedailera Spedali Civili di Brescia

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Brescia : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Catania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Catania : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Fierenze : Azienda Ospedaliera Universitaria Careggi

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Firenze : Azienda Ospedaliera Universitaria Careggi

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Firenze : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Firenze : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Firenze : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Firenze : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Genova : Azienda Ospedaliera Universitaria San Marino di Genova

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Genova : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Genova : University Hospital San Martino, Department of Hematology and Oncology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Genova : IRCCS Azienda Ospedaliera Universitaria San Martino

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Genova : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Genova : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Meldola : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Milano : Niguarda Ca'Granda Hospital, Department of Hematology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Milano : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Milano : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Modena : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Monza : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Naples : AORN

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Napoli : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Napoli : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Napoli : Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Novara : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Novara : Azienda Ospedaliera Universitaria Maggiore

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Palermo : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Palermo : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Parma : Azienda Ospedaliero Universitaria di Parma

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Pescara : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Pescara : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Piacenza : AUSL di Piacenza - Ospedale Guglielmo da Saliceto

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Pisa : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Pisa : Azienda Ospedaliero-Universitaria Pisana, Dipartimento di Oncologia

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ravenna : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ravenna : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Rimini : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Rimini : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Rionero in Vulture (PZ) : IRCCS CROB - Unita Operativa Complessa (UOC) di Ematologia e Trapianto di Cellule Staminali Emopoietiche

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Roma : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Roma : Azienda Policlinico Umberto I, Dipartimento di Biotechnologie Cellulari ed Ematologia

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Roma : Ospedale Sant' Eugenio - Universita Tor Vergata, Unita Operativa Complessa di Ematologia

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Roma : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Roma : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Roma : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Rome : Sapienza University of Rome, Department of Hematology

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Rome : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Rozzano : IRCCS Istituto Clinico Humanitas

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Rozzano MI : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Terni : Azienda Ospedaliera S. Maria di Terni

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Terni : Local Institute

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Torino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Torino : Azienda Ospedaliera Città della Salute e della Scienza di Torino

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Torino : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Torino : Azienda Ospedaliera Universitaria San Giovanni

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Torino : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Torino : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Udine : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Vimercate MB : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Akita-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Chuo-ku :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Fukuoka : Celgene Trial Sites

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma

View More »

Fukuoka :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Isehara : Celgene Trial Site

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Isehara :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Kamogawa : Clinical Trial Site

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Kamogawa-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Kawagoe : Celgene Trial Sites

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Kawagoe-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Koto-ku :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Kumamoto-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kyoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Kyoto :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Kyoto-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Maebashi-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Nagoya : Celgene Trial Sites

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Nagoya : Updated

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Nagoya :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Nagoya-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Niigata : Celgene Trial Sites

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Niigata :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Ogaki-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Okayama : Celgene Trial Sites

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Okayama :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Okayama-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Sapporo :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Sendai :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Shibukawa :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Shibukawa-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Shibuya-ku : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Shibuya-ku :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Tokushima :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Tokushima-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Tokyo : Celgene Trial Site

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Tokyo : Updated

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Toyama-shi : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Utsunomiya :

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Anyang : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Busan :

Velcade (Bortezomib) Consolidation After Transplant

Daegu : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Daejeon :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Daejeon : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

View More »

Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Gwangju : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hwasun Gun :

Velcade (Bortezomib) Consolidation After Transplant

Hwsun-eup, Hwasun-gun : Je-Jung Lee

TCD Followed by autoSCT for Newly Diagnosed MM Patients

Incheon : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Inchon : Gachon University Gil Hospital

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Seoul :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Seoul : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Seoul : Seoul National University Hospital

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Riga :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Klaipeda :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Vilnius :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Skopje :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Georgetown : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ipoh : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Kuching : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Tlalpan : Instituto Nacional de Cancerologia

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toluca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Amsterdam : VU Medical Center

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Nieuwegein : Antonius Ziekenhuis Nieuwegein

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Rotterdam : Erasmus University Medical Center

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Utrecht : Universitair Medisch Centrum UMC

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Utrecht : Uni.Med Center Utrecht

Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma

View More »

Utrecht : UMC Utrecht

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

Auckland : Middlemore Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Auckland : Middlemore Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Auckland : Auckland City Hospital, Auckland District Health Board

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Auckland City : North Shore Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Christchurch : Canterbury Health Laboratories

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

View More »

Christchurch : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Christchurch : Canterbury Health Laboratories

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Christchurch : Christchurch Hospital

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Grafton Auckland : Auckland City Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Grafton, Auckland : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Hamilton : Waikato Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Newtown, Wellington : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Palmerston North : Palmerston North Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Wellington : Wellington Regional Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Bialystok :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Bialystok : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Brzozow :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Bytom :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Chorzow :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

View More »

Chorzow : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Gdansk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Katowice :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Legnica :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Lublin :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Lublin : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Lublin : SPSK1 Klinika Hematologii

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Lublin : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Opole :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Poznan :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Poznan : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Rzeszow :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Slupsk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Slupsk : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Warsaw : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Warszawa :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Warszawa : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Warszawa : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Warszawa Poland :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Wroclaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Wroclaw :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Wroclaw : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Wroclaw : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Zamosc : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Zamosc :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Braga : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Coimbra : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Lisboa : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Matosinhos : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Porto : Instituto Portugues de Oncologia do Porto Francisc

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

View More »

Porto : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Ponce : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

San Juan : Auxilio Cancer Center

Connect® MM- The Multiple Myeloma Disease Registry

Brasov : Emergency County Clinical Hospital Brasov

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Brasov : Spitalul Clinic Judetean de Urgenta Brasov

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Brasov : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Bucaresti : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Bucharest : "Coltea" Clinical Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

View More »

Bucharest : Emergency University Hospital

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Bucuresti : Spitalul Universitar de Urgenta Bucuresti, Sectia Clinica Hematologie

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Bucuresti : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Lasi : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Ekaterinburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Krasnodar :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Krasnogorsk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Moscow : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Nizhny Novgorod : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

View More »

Novosibirsk : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Petrozavodsk : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Petrozavodsk : State Healthcare Institution "Republican Hospital named after V.A. Baranov"

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Podolsk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Saint Petersburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Saint-Petersburg :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Saint-Petersburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Saint-Petersburg : Russian Research Institute of Hematology and Transfusiology of Federal Medicobiological Agency

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Saint-Petersburg : Saint Petersburg State Medical University

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Saint-Petersburg : City Clinical Hospital #31

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Saint-Petersburg : V.A. Almazov Federal Centre of Heart, Blood and Endocrinology

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Samara : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Samara : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Saransk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

St Petersburg :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

St. Petersburg : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

St. Petersburg : Federal State Institution "Russian Scientific and Research Institute of Hematology and Transfusiology" of Federal Medical Biological Agency

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Ulyanovsk :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Volgograd : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Vologda :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Riyadh : King Faisal Specialist Hospital and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Singapore : Novartis Investigative Site

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Singapore : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Singapore : National University Hospital (Cancer Institute)

Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma

Singapore : National University Cancer Institute

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Singapore : Singapore General Hospital, Haematology Department

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Bratislava : Univerzitna nemocnica Bratislava

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Ljubljana :

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

Alcalá de Henares : Hospital Principe de Asturias

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Alcorcón : Fundación Hospital Alcorcón

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Badalona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Badalona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Badalona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

View More »

Badalona : Hospital Germans Trias i Pujol

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Badalona : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Badalona : Hospital de Badalona Germans Trias i Pujol

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Badalona : Hospital Universitari Germans Trias I Pujol

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

Badalona-Barcelona : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Barcelona : Hospital de la Santa Creu i Sant Pau

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Barcelona : Hospital Clinic de Barcelona

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Barcelona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Barcelona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Updated

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Barcelona :

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Barcelona : Hospital Clinic I Provincial de Barcelona

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Barcelona : Hospital Clínic

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Barcelona : Institut català d'Oncología

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Barcelona : Research Site

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Barcelona : Hospital Clinic i Provincial de Barcelona

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Barcelona : Hospital Clinic I Provincial

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Barcelona : Hospital Germans Trias I Pujol

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Barcelona : Local Institution

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Barcelona : Local Institution

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Barcelona : Local Institution

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Barcelona : Hospital Clínic i Provincial de Barcelona

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Barcelona : Hospital Universitari Germans I Pujol

Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma

Barcelona : ICO - Duran i Reynals, Hospitalet de Llobregat

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Barcelona : H. Vall d'Hebron, Barcelona

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Barcelona : Hospital Clinic i Provincial de Barcelona

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Barcelona : Hospital del Mar

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Barcelona : Hospital de la Santa Creu i Sant Pau

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Barcelona : Hospital de la Santa Creu i Sant Pau

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

Barcleona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Barcleona :

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Bilbao : Hospital de Cruces

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Cáceres : Complejo Hospitalario de Cáceres

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Do